Relevance of Comet Assay and Phosphorylated-Hsp90α in Cancer Patients' Peripheral Blood Leukocytes as Tools to Assess Cisplatin-based Chemotherapy Clinical Response and Disease Outcome

Cisplatin (cPt) is a commonly used treatment for solid tumors. The main target of its cytotoxicity is the DNA molecule, which makes the DNA damage response (DDR) crucial for cPt-based chemotherapy. Therefore, it is essential to identify biomarkers that can accurately predict the individual clinical...

Full description

Saved in:

Bibliographic Details
Published in:	The journal of histochemistry and cytochemistry Vol. 72; no. 3; p. 173
Main Authors:	Sottile, Mayra L, Gómez, Laura C, Redondo, Analía, Ibarra, Jorge, García, María B, Gonzalez, Lucía, Vargas-Roig, Laura M, Nadin, Silvina B
Format:	Journal Article
Language:	English
Published:	United States 01.03.2024
Subjects:	Cisplatin - pharmacology Cisplatin - therapeutic use Comet Assay DNA Damage Humans Leukocytes Neoplasms - drug therapy Neoplasms - genetics human leukocytes phospho-Hsp90α prognostic markers 53BP1 DNA damage predictive markers γH2AX platinum analogues oncology
ISSN:	1551-5044, 1551-5044
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!